Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors by Bruel, Amélie et al.
Synthesis of new pyridazino[4,5-b]indol-4-ones and
pyridazin-3(2H)-one analogs as DYRK1A inhibitors
Ame´lie Bruel, Romain Be´ne´teau, Myle`ne Chabanne, Olivier Lozach, Re´my Le
Guevel, Myriam Ravache, He´le`ne Be´ne´detti, Laurent Meijer, Ce´dric Loge´,
Jean-Michel Robert
To cite this version:
Ame´lie Bruel, Romain Be´ne´teau, Myle`ne Chabanne, Olivier Lozach, Re´my Le Guevel, et al..
Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A




Submitted on 21 Nov 2014
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs 
as DYRK1A inhibitors 
Amélie Bruela, Romain Bénéteaua, Mylène Chabannea, Olivier Lozachb, Rémy Le Guevelc, Myriam 
Ravachec, Hélène Bénédettid, Laurent Meijerb,e, Cédric Logéa,, Jean-Michel Roberta 
a Université de Nantes, Nantes Atlantique Universités, Laboratoire de Chimie Thérapeutique, Cibles et Médicaments des Infections et du Cancer, IICIMED-EA 
1155, UFR Sciences Pharmaceutiques, 1 rue Gaston Veil, Nantes F-44035 Cedex 1, France 
b Protein Phosphorylation & Human Disease group, CNRS, USR 3151, Station Biologique, B.P. 74, 29682 Roscoff Cedex, France 
c Plate-forme ImPACcell, UMS-3480, Université de Rennes 1, Campus de Villejean, 2 avenue du Professeur Léon Bernard, 35043 Rennes Cedex, France 
dCentre de Biophysique Moléculaire, CNRS, UPR 4301, Université d'Orléans et INSERM, rue Charles Sadron, 45071 Orléans Cedex 2, France 
eManRos Therapeutics, Centre de Perharidy, 29680 Roscoff, France 
 
 
Abstract : New pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs were synthesized and their inhibitory activities against 
DYRK1A, CDK5/p25, GSK3α/β and p110-α isoform of PI3K evaluated using harmine as reference. Both furan-2-yl 10 and pyridin-4-yl 19 
from the two different series, exhibited submicromolar IC50 against DYRK1A with no activities against the three other kinases. In addition, 
compound 10 exhibited antiproliferative activities in the Huh-7, Caco2 and MDA-MB-231 cell lines. 
 
Harmine and other members of the family of β-carboline alkaloids have been shown to inhibit the dual-specificity tyrosine 
phosphorylation-regulated kinase 1A (DYRK1A), a serine/threonine kinase implicated in Down syndrome, and to reduce the levels of 
multiple phosphorylated forms of tau protein that are important in the pathological progression of Alzheimer's disease (AD).[1-3] DYRK1A 
belongs to the DYRK family within the CMGC group (cyclin-dependent kinases (CDKs), mitogen-activated protein kinases (MAP 
kinases), glycogen synthase kinases (GSK) and CDK-like kinases (CLKs)) of the eukaryote kinome. Although harmine represents a 
standard in terms of activity and selectivity, the numerous side eﬀects have led to the development and study of various natural and 
synthetic compounds, a number of them incorporating indolic or aza-indolic scaffolds (see meridianin, meriolin and lamellarin 
derivatives).[4] In particularly, harmine and derivatives exhibited cytotoxic activities against human cancer cell lines that could be (partly) 
attributed to its planar tricyclic system able to intercalate DNA.[5,6]  
 
Previously, as an initial attempt to design new kinase inhibitors focused on a pyridazino[4,5-b]indol-4-one scaffold, we already 
prepared compound 1 showing micromolar IC50 value against DYRK1A (Fig. 1).
[7] Due to its structural analogy with harmine, we thought 
that this molecule could be a good starting template for further optimization. Thus, we focused our efforts on the introduction of various 
(het)aryl substituents at position 1 of this privileged structure and compared the biological results with some of their non-planar analogs 





















compound 1 (R = CH3)
DYRK1A (IC50 = 5 µM)  
Figure 1. General structures of synthesized compounds. 
 
Pyridazino[4,5-b]indol-4-ones 7-10 were classically prepared starting from ethyl 5-methoxy-1H-indole-2-carboxylate. Friedel-Crafts 
acylation using a wide variety of acid chlorides in the presence of Tin(IV) chloride in methylene chloride-nitromethane gave indoles 3-6 
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Pyridazin-3(2H)-ones 15-19 can be prepared from bromomaleic anhydride, which reacted with hydrazine sulfate in water under 
refluxing conditions, to give 4-bromo-1,2-dihydropyridazine-3,6-dione (12) in 89% yield.[10] Condensation of p-anisidine with compound 
12, in the presence of copper powder, in N-methyl-2-pyrrolidone (NMP) at 160°C led to compound 13 which can be monochlorinated at 
the C-6 position with excess phosphorus oxychloride (POCl3) at 100°C during one hour to give intermediate 14.
[11,12] Introduction of a 
methyl substituent (15) was successful with trimethylaluminium under Pd(PPh3)4 catalyzed conditions in refluxing dioxane
[13] whereas 
Suzuki cross-coupling with various boronic acids or pyridine-4-boronic acid pinacol ester, under microwave irradiation, afforded 














































Scheme 2. Reagents and conditions: (a) Hydrazine sulfate, H2O, reflux, 10 h, 89%; (b) p-anisidine, Cucat, NMP, 160°C, 4 h, 87%; (c) POCl3 (6éq), 100°C, 1 h, 
81%; (d) AlMe3, Pd(PPh3)4, 1,4-dioxane, reflux, 24 h, 20%; (e) Boronic acids or pyridine-4-boronic acid pinacol ester, Na2CO3 (2M), Pd(PPh3)4, toluene or DMF, 
110°C (mW), 15-35 min, 20-82%. 
 
The final products were tested against four representative kinases DYRK1A, CDK5/p25, GSK3/β and p110- isoform of PI3K 
chosen for their involvement in regulation processes including neurodegenerative diseases or cancer (Table 1).[7,15] The biological results 
are very heterogeneous, except on CDK5/p25 where all the compounds displayed IC50 values above 10 µM. In the pyridazino[4,5-b]indol-
4-one series (7-10), compound 10 bearing a furan-2-yl substituent showed a significant submicromolar IC50 value of 0.22 µM against 
DYRK1A, only 4-fold less active than harmine, with no activity towards the other kinases. From this data alone, it appears that particular 
variations at position 1 of the pyridazino[4,5-b]indol-4-one scaffold seem to be allowed for a good inhibitory activity against this enzyme, 
although the results observed for compounds 7-9 are contradictory. Also, when we compared compounds 1 and 10 with their ring-opened 
analogs 15 and 18 from the pyridazin-3(2H)-one series, a loss of activity was observed while the unique compound 19 containing a 
pyridine moiety at position 6 of the pyridazin-3(2H)-one series displayed a pronounced inhibitory activity against DYRK1A (IC50 = 0.61 
µM). Such structure-activity relationships are difficult to interpret and it is plausible that different binding modes in the ATP binding site 
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Compounds R R’ DYRK1A CDK5/p25 GSK3/β PI3K 
1 CH3  5 >10 >10 NT 
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16  
 
>10 >10 >10 >10 
17  MeO
 
5.1 >10 2.5 NT 
18  
O  
>10 >10 >10 >10 
19  N
 
0.61 >10 9.6 >10 
Harmine   0.06 8 >10 NT 
 
A purely hypothetical binding mode for the most efficient compound 10 inside the ATP-binding site of DYRK1A (pdb code: 2WO6) 
is shown in Figure 2.[16,17] In contrast to harmine which interacts with residue Leu241 (hinge region) via a key hydrogen bond to its 
methoxy group,[18] compound 10 appears to involve its pyridazinone ring through hydrogen bonds with the hinge region (backbone atoms 
of Glu239 and Leu241), thereby positioning the five-membered aromatic furan ring in a - stacking interaction with the gatekeeper 
residue (Phe238). Selectivity over CDK5 and GSK3 could be attributed to an additional direct or water-mediated hydrogen bond 










The cytotoxic effects of these compounds were then determined against six human cancer cell lines (hepatocellular carcinoma Huh-7, 
colorectal adenocarcinoma Caco2, colorectal carcinoma HCT-116, breast carcinoma MDA-MB-231, prostate carcinoma PC3 and lung 
carcinoid NCI-H727) and one normal cell line (fibroblasts) (Table 2).[7] Only compound 10 exhibited anti-proliferative activities in the 
Huh-7, Caco2 and MDA-MB-231 cell lines with an IC50 value lower than 1 μM, probably by exerting a cytostatic effect, while other 
compounds had no effect on cell proliferation. However, these anti-proliferative effects may not be correlated with the compounds’ ability 
to inhibit the DYRK1A protein kinase as compounds 8 or 19 were inactive on these cell lines.
 
Table 2. Anti-proliferative activity in various cell lines (IC50 values in µM; NT = not tested; values lower than 1 µM are highlighted in bold; the number in brackets 
indicate the percentage of cell growth decrease).a 
 
Compounds Huh-7 Caco2 HCT-116 MDA-MB-231 PC3 NCI-H727 Fibroblasts 
1 3 8 15 5 7 5 20 
7 NT NT NT NT NT NT NT 
8 > 25 > 25 > 25 > 25 > 25 > 25 > 25 
9 > 25 > 25 > 25 > 25 > 25 > 25 > 25 
10 0.25 (50%) 0.6 3 (50%) 0.3 (50%) > 25 > 25 > 25 
15 NT NT NT NT NT NT NT 
16 > 25 > 25 > 25 > 25 > 25 > 25 > 25 
17 NT NT NT NT NT NT NT 
18 > 25 > 25 > 25 > 25 > 25 > 25 > 25 
19 > 25 > 25 > 25 > 25 > 25 > 25 > 25 
 
a Assays were performed in triplicate. Reference compounds used (not shown) were DMSO, taxol and doxorubicin. 
 
DYRK1A has been shown to be expressed ubiquitously, and its functional role in cancer is still largely obscure. Therefore, the attractive 
inhibitory profiles of both compounds 10 and 19 (from the two different series) against DYRK1A and selected cancer cell growth make 
them candidates for further evaluations (i.e. a screen against a wide variety of kinases to get an overall view of their selectivity), even if 
biological results for the pyridazino[4,5-b]indol-4-one scaffold (10) are probably due to combined interactions with several relevant 
targets that could imply undesirable side-effects. 
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1H and 13C NMR spectra for compounds 10 and 19 can be found in the online version. 
